Taylor & Francis (Royaume-Uni)
MAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are
MAbs is a multi-disciplinary journal dedicated to the art and science of antibody research and development. The journal has a strong scientific and medical focus, but also strives to serve a broader readership. The articles are thus of interest to scientists, clinical researchers, and physicians, as well as the wider MAb community, including our readers involved in technology transfer, legal issues, investment, strategic planning and the regulation of therapeutics. Relevant topics include (but are not be limited to): Antibody engineering and selection Targets relevant to cancer, immune-mediated disorders, and other diseases Non-clinical studies of antibodies, e.g., mechanism of action studies, safety and efficacy studies in animals Manufacturing Clinical studies Regulatory review of antibody therapeutics Post-approval topics, e.g., pricing, reimbursement and markets Patents Emerging markets for antibody therapeutics, including China and India
